Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc. (PacBio)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: PacBio is a development-stage company developing a third-generation DNA sequencing platform called the PacBio RS, based on proprietary Single Molecule, Real-Time (SMRT) technology. The company has not yet commercially launched its primary product, with a planned launch in the second quarter of 2011. Revenue to date is derived solely from U.S. government grants.
Key Financial Metrics
| Metric (in thousands) | 2010 | 2009 |
|---|---|---|
| Grant Revenue | $1,674 | $135 |
| Research & Development Expenses | $111,821 | $75,879 |
| Sales, General & Administrative Expenses | $30,087 | $12,326 |
| Net Loss | $(140,166) | $(87,703) |
| Cash, Cash Equivalents & Investments | $283,674 | $92,735 |
| Working Capital | $272,274 | $85,326 |
| Backlog | $24.0 million | N/A |
Note: The company reported a net loss per share of $(14.10) for 2010. There is no product revenue; all revenue is from government grants.
Material Changes vs. Prior Period
- Capital Raise: The company completed its Initial Public Offering (IPO) in November 2010, raising approximately $210.8 million in net proceeds. Additionally, it raised $106.1 million from the issuance of Series F convertible preferred stock in mid-2010.
- Expense Growth: Total operating expenses increased by approximately $53.7 million (61%) compared to 2009. This was driven by a $35.9 million increase in R&D (due to prototype materials and personnel expansion) and a $17.8 million increase in SG&A (due to sales force expansion and marketing).
- Liquidity: Cash and investments increased by $190.9 million year-over-year, primarily due to the IPO and preferred stock issuance, offset by $122.0 million in cash used for operations.
- Inventory: The company began capitalizing pre-launch instrument inventory in Q4 2010, resulting in $6.9 million in inventory on the balance sheet, compared to zero in 2009.
Outlook, Risks, and Contingencies
- Commercial Launch: The company plans to commercially launch the PacBio RS in the second quarter of 2011. Revenue from limited production release units shipped in 2010 is deferred until full commercial specifications are met and accepted.
- Profitability: The company expects to continue to incur significant losses and negative cash flow for the foreseeable future as it scales manufacturing and sales operations.
- Legal Proceedings:
- Helicos Biosciences: Named as a defendant in a patent infringement lawsuit filed in August 2010. The company denies allegations and has filed counterclaims. No liability has been recorded as the outcome is uncertain.
- Life Technologies: Successfully won a patent interference ruling in January 2011, resulting in the cancellation of Life Technologies' claims involved in the dispute.
- Key Personnel Risk: CEO Hugh Martin has been diagnosed with multiple myeloma. While currently not affecting his performance, the company notes uncertainty regarding his future ability to lead.
- Manufacturing Risks: The company relies on single-source suppliers for critical components (semiconductor chips, optics, lasers) and faces challenges in scaling manufacturing yields for consumables (SMRT Cells).
Investor Verification Checklist
- Revenue Recognition: Verify the timeline for the commercial launch of the PacBio RS and the criteria for recognizing revenue from the $24 million backlog.
- Burn Rate: Assess the sustainability of the $283.7 million cash position against the projected operating losses and capital expenditure requirements for manufacturing scale-up.
- Legal Exposure: Monitor the status of the Helicos Biosciences litigation and potential financial impact of an unfavorable ruling.
- Supply Chain: Confirm the company's ability to secure alternative suppliers for single-source components and improve manufacturing yields for SMRT Cells.
- Management Continuity: Monitor the health status of CEO Hugh Martin and the company's succession planning.